RBC Capital analyst Gregory Renza maintained a Buy rating on BELLUS Health (BLU - Research Report) on November 14 and set a price target of...
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on BELLUS Health (BLU – Research Report) today and set a price target of $16.00. The...
RBC Capital analyst Gregory Renza maintained a Buy rating on BELLUS Health (BLU – Research Report) on May 11 and set a price target of $14.00. The...
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on BELLUS Health (BLU – Research Report), with a price target...
RBC Capital analyst Gregory Renza maintained a Buy rating on BELLUS Health (BLU – Research Report) on April 1 and set a price target of $14.00...
BTIG analyst Justin Zelin maintained a Buy rating on BELLUS Health (BLU – Research Report) on February 23 and set a price target of $18.00. The...
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on BELLUS Health (BLU – Research Report) on January 24 and set a price target of...
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on BELLUS Health (BLU – Research Report), with a price target...
After H.C. Wainwright and Evercore ISI gave BELLUS Health (NASDAQ: BLU) a Buy rating last month, the company received another Buy, this time from...
The week started in the best possible way for BELLUS Health (BLU) stock. While the main indexes bled in Monday’s session, BLU shares took the up...
In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on BELLUS Health (BLU – Research Report), with a price...
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on BELLUS Health (BLU – Research Report) today and set a price target of $14.00. The...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BELLUS Health (BLU – Research Report) and...
In a report issued on November 15, Gregory Renza from RBC Capital maintained a Buy rating on BELLUS Health (BLU – Research Report), with a price...
BELLUS Health (BLU) is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.